#NEJMVisualAbstract: Teprotumumab for the Treatment of Activ
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food and Drug Administration–approved medical therapy is available. Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of this disease.

In the randomized trial, A total of 41 patients were assigned to the teprotumumab group and 42 to the placebo group. Among patients with active thyroid eye disease, teprotumumab resulted in better outcomes with respect to proptosis, Clinical Activity Score, diplopia, and quality of life than placebo; serious adverse events were uncommon.

Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1910434
Dr. N●●●●a S●●h and 2 other likes this1 share
Like
Comment
Share